Kay Foland
Psychiatric/Mental Health · Rapid City, SDNPI 1538213541
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $450 and has fallen 50.4% since, to $223 in 2025.
Across 32 payments — averaging $37.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$217
- Alkermes, Inc.$189
- Vanda Pharmaceuticals Inc.$157
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$146
- E.r. Squibb & Sons, L.L.C.$125
- Otsuka America Pharmaceutical, Inc.$80
- plus $293 from 6 others
What the payments were for
- Food & beverage$1,207100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $217 |
| Alkermes, Inc. | 4 | $189 |
| Vanda Pharmaceuticals Inc. | 3 | $157 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $146 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| AbbVie | 3 | $72 |
| Neurocrine Biosciences, Inc. | 4 | $70 |
| Lundbeck LLC | 2 | $30 |
| Johnson & Johnson | 1 | $26 |
| Livanova USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,207 in reported general payments places this provider in the 70th percentile of 77 psychiatric/mental health providers in South Dakota.
See all psychiatric/mental health providers in South Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 20 | $127,554 |
| IngrezzaValbenazine Tosylate | 12 | $91,233 |
| Invega SustennaPaliperidone Palmitate | 21 | $81,646 |
| Aripiprazole | 188 | $25,794 |
| Quetiapine Fumarate | 297 | $7,448 |
| Paliperidone ErPaliperidone | 14 | $5,715 |
| Buspirone Hcl | 199 | $5,234 |
| Risperidone | 161 | $4,373 |
| Olanzapine | 140 | $4,269 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 70 | $4,240 |
| Bupropion XlBupropion Hcl | 126 | $3,861 |
| Atomoxetine Hcl | 13 | $3,371 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 92 | $3,192 |
| Clozapine | 29 | $3,084 |
| Divalproex Sodium ErDivalproex Sodium | 35 | $2,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $217 | $127,55420 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $70 | $91,23312 claims |
| Johnson & JohnsonInvega Sustenna | $26 | $81,64621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 77 psychiatric/mental health providers in South Dakota.
Other psychiatric/mental health in Rapid City
- Jennifer ErdmanRapid City$6K
- Amy NewstromRapid City$3K
- Kristen CorkleRapid City$2K
- Lisa KautzmanRapid City$2K
- Sydnie GamrothRapid City$1K
- Steven DaryRapid City$1K
- Tamber WhiteRapid City$1K
- Laura SchirberRapid City$1K
- Megan BurgardRapid City$922
- Leslie MossRapid City$918
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.